公开(公告)号：US20230146593A1

公开(公告)日：2023-05-11

申请号：US17910698

申请日：2021-03-12

Applicant: AMGEN INC.

Inventor： Sophia K. Khaldoyanidi ,  Dirk Nagorsen ,  Tara Arvedson ,  Suresh Agarwal ,  Vijay Vishesh Upreti ,  Steven Yea

IPC: A61K39/395 ,  A61K38/17 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K38/1793 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention relates to medical combination products comprising (i) at least one antibody construct comprising at least one domain which binds to a target antigen expressed on the surface of a cell and at least one other domain which binds to CD3 as well as (ii) at least one molecule that is inhibitor/antagonist of TNF/TNFR reducing TNF/TNFR signaling and/or an inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling, wherein a first dose of said inhibitor/antagonist is administered before administration of a first dose of said antibody construct. Furthermore, the invention provides therapeutic and preventive methods and medical uses of said combination products, as well as a kit comprising said at least one antibody construct and at least one antagonist/inhibitor of TNF or IL6 or its cognate receptor, wherein the interaction of said antagonist/inhibitor of TNF or an inhibitor/antagonist of IL6 with its cognate receptor reduces, mitigates, prevents, or treats cytokine release syndrome.